CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 610
- Registration Number
- NCT03084718
- Locations
- 🇺🇸
Chiesi Investigational Site, Greenfield, Wisconsin, United States
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 72
- Registration Number
- NCT03056326
- Locations
- 🇧🇪
SGS Life Sciences, Antwerpen, Belgium
Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 36
- Registration Number
- NCT03004495
- Locations
- 🇬🇧
Quintiles CPU, London, UK, United Kingdom
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 61
- Registration Number
- NCT03004417
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd, Manchester, United Kingdom
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 5
- Registration Number
- NCT02998879
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1130
- Registration Number
- NCT02986321
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT02975843
Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT02970630
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇮🇹Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹Policlinico "A. Gemelli", Rome, Italy
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 118
- Registration Number
- NCT02815488
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 26
- Registration Number
- NCT02787967
- Locations
- 🇩🇰
BørneAstmaKlinikken, Hans Knudsens Plads 1A,, Copenaghen, Denmark
© Copyright 2024. All Rights Reserved by MedPath